ClinicalTrials.gg
CompletedNCT00662272H-100-001Updated Mar 17, 2010

Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant

A Phase 1 interventional study of Fluzone vaccine with JVRS-100 adjuvant and Fluzone vaccine in Influenza, sponsored by Colby Pharmaceutical Company. Completed at 2 sites in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-03-17.

Sponsored by Colby Pharmaceutical Company · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 966 studies in Influenza, Human with a site in United States — 60 open to participants now, 85 under way, 7 of them phase 3. Influenza, Human · United States.

Enrollment
529th of 843
128 · median 270
Started
2008
with 46 others
Phase 1
177 of 966
10 open now
Registered
148th of 966
by date

Among the 966 studies in Influenza, Human with a site in United States, this one is the 529th largest by enrollment of the 843 interventional ones that give a count, is one of 47 that started in 2008, is one of 177 in phase 1, and was the 148th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

60 of the 966 studies in Influenza, Human with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 966 studies in Influenza, Human with a site in United States, or all of them as a file.
02

Study summary

This study is designed to assess safety, tolerability and immunogenicity of Fluzone® vaccine with four dose levels of JVRS-100 adjuvant compared to Fluzone® vaccine alone in healthy adults 18-49 years of age.

Read the detailed description

The purpose of this trial is to evaluate the safety and tolerability of graded, ascending doses of JVRS-100 adjuvant when administered in combination with a vaccine antigen.

03

Conditions studied

  • Influenza

Browse trials for

Keywords

  • Flu
  • Influenza vaccine
  • Adjuvant
  • Safety of an adjuvanted vaccine
  • Immune response to an adjuvanted vaccine
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • able to understand the study and provide written
  • be age 18 to 49 years
  • be in good general health, without significant medical history, physical examination findings, or abnormal laboratory results
  • be available for the study duration, including all planned follow-up visits
  • female subjects of child bearing potential must not be pregnant and agree to be correctly using an efficacious hormonal method of or intrauterine device for at least 1 month before the study and during the study

Exclusion criteria

Exclusion Criteria:

  • have allergy to eggs or other components of the vaccine
  • have had an influenza vaccine within 3 years preceding the screening visit
  • have a history of severe reaction of any kind to conventional influenza vaccines
  • have or suspected immunodeficiency disorder, including leukemia, lymphoma, generalized , or treatment with medications, including , alkylating agents, antimetabolites, or radiation therapy
  • have a history of an disorder, including systemic lupus, rheumatoid arthritis, scleroderma, other collagen vascular disease, multiple sclerosis, etc. Psoriasis limited to cutaneous manifestations is not an exclusion criterion.
  • have prior history of anaphylaxis to foods, hymenoptera stings, vaccines or drugs
  • have had transfusion of blood or treatment with any blood product, including intramuscular or intravenous serum globulin within 3 months of the Screening Visit or anticipated through the study period
  • have received another vaccine within 30 days preceding the screening visit or anticipated through the study period
  • have participation in another clinical trial within 60 days of the screening visit
  • have a positive serum or urine pregnancy test prior to vaccination or plan on a pregnancy during study period
  • have abnormalities on laboratory assessment
  • be seropositive to or or positive for
  • be positive for anti-nuclear antibodies
  • have a physical examination indicating any medical condition
  • have a body temperature >38.1°C (100.6°F) or acute illness within 3 days prior to vaccination
  • intention to travel out of the area prior to the study visit on Day 28 of the study
  • have a history of excessive alcohol consumption, drug abuse, significant psychiatric illness
  • have the intention to increase normal exercise routine, participate in contact sports or strenuous weight lifting or to initiate vigorous exercise from Screening until after Day 28 of the study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
128 participants (actual)

Study arms

  • Experimental
    1

    Arm includes treatment with Fluzone® vaccine mixed with study product JVRS-100 adjuvant

    Biological: Fluzone vaccine with JVRS-100 adjuvant

  • Active comparator
    2

    Arm includes treatment with half adult dose of Fluzone® vaccine

    Biological: Fluzone vaccine

  • Active comparator
    3

    Arm includes treatment with full adult dose Fluzone® vaccine

    Biological: Fluzone vaccine

Interventions

  • BiologicalFluzone vaccine with JVRS-100 adjuvant

    Drug page: Adjuvant

    One vaccination on Day 0 with Fluzone vaccine at 22.5µg mixed with JVRS-100 adjuvant at one of four dose levels (7.5µg, 25µg, 75µg, 225µg) given by IM injection in the upper deltoid.

    Also known as: Fluzone vaccine, adjuvant

  • BiologicalFluzone vaccine

    One vaccination on Day 0 with Fluzone vaccine at 22.5µg given by IM injection in the upper deltoid.

    Also known as: Flu vaccine

  • BiologicalFluzone vaccine

    One vaccination on Day 0 with Fluzone vaccine at 45µg given by IM injection in the upper deltoid.

    Also known as: Flu vaccination

06

What researchers measure

Primary outcomes

  1. Comparison of adverse events between treatment groups

    Time frame: Active Study Duration

  2. Dose-response analysis of HAI geometric mean titers (GMT)

    Time frame: 5 time points

Secondary outcomes

  1. Safety endpoints include between treatment group analyses of all safety parameters as described for the primary endpoint for each ascending dose cohort.

    Time frame: 2 periods

  2. Seroprotection and seroconversion rates to various antigens, distribution of antibody titers, duration of HAI antibody titers, and assessment of cross-reactive HAI responses against "drifted" strains.

    Time frame: 5 time points

07

Study locations

2 sites
  • Miami Research Associates
    Miami, Florida 33143, United States
  • Johnson County Clin-Trials
    Lenexa, Kansas 66219, United States
08

References and documents

Publications

  • Betts RF, Treanor JJ. Approaches to improved influenza vaccination. Vaccine. 2000 Feb 25;18(16):1690-5. doi: 10.1016/s0264-410x(99)00508-3. PubMed 10689150 ↗
  • Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003 Jan 8;289(2):179-86. doi: 10.1001/jama.289.2.179. PubMed 12517228 ↗
  • Monto AS, Kioumehr F. The Tecumseh Study of Respiratory Illness. IX. Occurence of influenza in the community, 1966--1971. Am J Epidemiol. 1975 Dec;102(6):553-63. doi: 10.1093/oxfordjournals.aje.a112193. PubMed 1202957 ↗
  • Barker WH. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970-78. Am J Public Health. 1986 Jul;76(7):761-5. doi: 10.2105/ajph.76.7.761. PubMed 3717461 ↗
  • Glezen WP. Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev. 1982;4:25-44. doi: 10.1093/oxfordjournals.epirev.a036250. No abstract available. PubMed 6754408 ↗
  • Pfleiderer M, Lower J, Kurth R. Cold-attenuated live influenza vaccines, a risk-benefit assessment. Vaccine. 2001 Dec 12;20(5-6):886-94. doi: 10.1016/s0264-410x(01)00386-3. PubMed 11738754 ↗
  • Hilleman MR. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine. 2002 Aug 19;20(25-26):3068-87. doi: 10.1016/s0264-410x(02)00254-2. PubMed 12163258 ↗
  • CBER. Guidance for Industry. Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines. May 2007. Available at hhtp://www.fda.gov/cber/guidelines.htm
  • Advisory Committee on Immunization Practices; Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA. Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006 Jul 28;55(RR-10):1-42. Erratum In: MMWR Morb Mortal Wkly Rep. 2006 Jul 28;55(29):800. PubMed 16874296 ↗
  • de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel). 2003;115:63-73. PubMed 15088777 ↗
  • Beyer WE, Palache AM, Luchters G, Nauta J, Osterhaus AD. Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res. 2004 Jul;103(1-2):125-32. doi: 10.1016/j.virusres.2004.02.024. PubMed 15163500 ↗
  • Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology. 2003 May-Jun;49(3):177-84. doi: 10.1159/000069172. PubMed 12679609 ↗
  • Amai M, Nojima M, Yuki Y, Kiyono H, Nagamura F. A review of criteria strictness in "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials". Vaccine. 2023 Aug 31;41(38):5622-5629. doi: 10.1016/j.vaccine.2023.07.072. Epub 2023 Aug 1. PubMed 37532612 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Oct 2008 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2008
First posted
Apr 21, 2008
Start
Jun 2008
Primary completionActual
Oct 2008
CompletionActual
Dec 2009
Last update
Mar 17, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00662272
Lead sponsor
Colby Pharmaceutical Company
First posted
Apr 21, 2008
Start date
Jun 2008
Primary completion
Oct 2008
Completion
Dec 2009
Last update
Mar 17, 2010

Study contacts

Thomas P Monath, MD
study director · Medical Monitor for Juvaris

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adjuvant

Start the discussion